ArticleChest2015
Racial difference in sarcoidosis mortality in the United States.
Article in Chest, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 111 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
111 citing papers in PubMed, 2 syntheses or guidelines pooled it, 246 citations in OpenAlex.
- Diagnostic delay of sarcoidosis: an integrated systematic review.Orphanet journal of rare diseases · 2024Pooled it
- A Systematic Review of the Spectrum of Cardiac Arrhythmias in Sub-Saharan Africa.Global heart · 2020Pooled it
- Prognostic impact ofBMC pulmonary medicine · 2026Article
- The Diagnostic Course of Sarcoidosis: A Population-Based Study Highlighting Risk Factors for a Delay in Diagnosis.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2026Article
- Outcomes of Lung Transplantation for Pulmonary Sarcoidosis Across Multiple Eras: A 25-Year Experience from a US Center.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2026Article
- Overlapping Sarcoidosis and Atopic Dermatitis in a Black American Female: Case Report of a Rare Coexistence and Novel Treatment Approach.The Journal of clinical and aesthetic dermatology · 2026Article
- Article
- Article
- A paradigm shift in corticosteroid therapy for sarcoidosis: a World Association of Sarcoidosis and Other Granulomatous Disorders Position Paper, endorsed by the Americas Association of Sarcoidosis and Other Granulomatous Disorders.The Lancet. Respiratory medicine · 2026Review
- Cardiovascular Manifestations and Immunobiology of Sarcoidosis.Arteriosclerosis, thrombosis, and vascular biology · 2026Review
- Article
- Racial, Ethnic, Sex, and Gender Equity for Inclusive Interstitial Lung Disease Research: An Official American Thoracic Society Research Statement.American journal of respiratory and critical care medicine · 2025Review
- CT Imaging Features of Pulmonary Sarcoidosis: Typical and Atypical Radiological Features and Their Differential Diagnosis.Medicina (Kaunas, Lithuania) · 2025Review
- Exploring gender and ethnic disparities in sarcoidosis: insights from the British Thoracic Society UK Interstitial Lung Disease Registry.BMJ open respiratory research · 2025Article
- Relapse Patterns and Clinical Outcomes in Cardiac Sarcoidosis: Insights from a Retrospective Single-Center Cohort Study.Journal of clinical medicine · 2025Article
- Race Comparisons in Patients With Cardiac Sarcoidosis: Insights From the Cardiac Sarcoidosis Consortium.Circulation. Arrhythmia and electrophysiology · 2025Observational
- Sinonasal Sarcoidosis: A Scoping Review of Demographics, Clinical Presentation, and Outcomes.Laryngoscope investigative otolaryngology · 2025Article
- Delays in Referral to Multidisciplinary Care for Black Individuals With Sarcoidosis.CHEST pulmonary · 2025Article
- Advancements in omics technologies: Molecular mechanisms of acute lung injury and acute respiratory distress syndrome (Review).International journal of molecular medicine · 2025Review
- Article
51 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on byResponse.2015
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundThe clinical presentation and outcome of sarcoidosis varies by race. However, the race difference in mortality outcome remains largely unknown.
methodsWe studied mortality related to sarcoidosis from 1999 through 2010 by examining data on multiple causes of death from the National Center for Health Statistics. We compared the comorbid conditions between sarcoidosis-related deaths with deaths caused by car accidents (previously healthy control subjects) and rheumatoid arthritis (chronic disease control subjects) in both African Americans and Caucasians.
resultsFrom 1999 through 2010, sarcoidosis was reported as an immediate cause of death in 10,348 people in the United States with a combined overall mean age-adjusted mortality rate of 2.8 per 1 million person-years. Of these, 6,285 were African American and 3,984 Caucasian. The age-adjusted mortality rate for African Americans was 12 times higher than for Caucasians. African Americans died at an earlier age than Caucasians. African Americans living in the District of Columbia and North Carolina and Caucasians living in Vermont had higher mortality rates. Although the total sarcoidosis age-adjusted mortality rate had not changed over the 12 year period studied, this rate increased for Caucasians (R = 0.747, P = .005) but not for African Americans. Compared with the control groups, pulmonary hypertension was significantly more common in individuals with sarcoidosis.
conclusionsThis nationwide population-based study exposes a significant difference in ethnicity and sex among people dying of sarcoidosis in the United States. Pulmonary hypertension investigation should be considered in all patients with sarcoidosis, especially African Americans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.